[An optimum dose-finding study of HR810 (CPR) in chronic respiratory tract infections]

Autor: Rinzo SOEJIMA, Jiro HINO, Masaru SUMI, Niro OKIMOTO, Susumu YAGI, Kuninori TSUKIYAMA, Toshiharu MATSUSHIMA, Masayoshi KAWANISHI, Yohmei HIRAGA, Mitsuhide OHMICHI, Akira WATANABE, Kotaro OIZUMI, Yoshihiro HONDA, Yutaka TOKUE, Masakichi MOTOMIYA, Kazuo SATO, Kosaku NAGAI, Shigeru SHIMODA, Kiyoshi KONNO, Izumi HAYASHI, Hiroshi OSHITANI, Hiroshi MIURA, Takashi INOUE, Hiroyuki KOBAYASHI, Kaoru SHIMADA, Takashi INAMATSU, Mieko GOTO, Shinichi OKA, Hajime GOTO, Yoshitaka NAKAMORI, Koji NARUI, Masayuki NOGUCHI, Tatsuo NAKAYA, Koichiro NAKATA, Iwao SAKURAI, Takeo IMAI, Fumio MATSUMOTO, Shigeki ODAGIRI, Kaneo SUZUKI, Kou MUROHASHI, Hiroshi TAKAHASHI, Yasuhiko ASHIKARI, Izumi KOYAMA, Toshikazu ISHII, Eiro TSUBURA, Masaru NAKAGAWA, Hideki NISHIKAWA, Yoshihiro TAKISHITA, Hiroyasu BANDO, Yoshihiro HASHIMOTO, Shinji ATAGI, Yukio MATSUMOTO, Mitsunobu YAMAMOTO, Tatsuya KONISHI, Yuji SUGIMOTO, Takuya SAKATA, Hiroaki HIRAI, Yutaka HITSUDA, Takao SASAKI, Kohei HARA, Masaki HIROTA, Shigeru KOHNO, Toshiaki HAYASHI, Naofumi SUYAMA, Yukishige MIYAZAKI, Yasumasa DOHTSU, Akira YASUOKA, Tatsuya KATSUMATA, Hiroshi YAMADA, Toshiaki YOSHIDA, Tsuyoshi NAGATAKE, Moritoshi AKIYAMA, Masakazu TAKASUGI, Mikio TAGUCHI, Kiwao WATANABE, Keizo MATSUMOTO, Masaru NASU, Jun GOTO, Hideaki SHIGENO, Yoichiro GOTO, Takayoshi TASHIRO, Hiroyuki NAGAI, Toru YAMAZAKI, Mitsunobu AKASHI, Atsushi SAITO, Hiroshi FUKUHARA, Hiroshi KANESHIMA, Yuei IRABU, Katsuyoshi SHIMOJI, Keizo KITSUKAWA, Yoshiteru SHIGENO, Nobuya OGAWA
Rok vydání: 1991
Předmět:
Zdroj: Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases. 65(1)
ISSN: 0387-5911
Popis: In order to determine the optimal dose of cefpirome sulfate (HR810, CPR) against respiratory tract infections (RTI), an optimal dose-finding study was conducted on cases of chronic RTI, and the clinical properties of the drug were compared with those of ceftazidime (CAZ). Inpatients with chronic RTI were randomly assigned to 3 groups: an HR 0.5 g group, receiving 0.5 g X 2/day of CPR an HR 1.0 g group, receiving 1.0 X 2/day of CPR and a CAZ group, receiving 1.0 g X 2/day of CAZ. As a rule, the drugs were administered by intravenous drip infusion for 14 days, after which period clinical efficacy, bacteriological response, safety, and utility were investigated. Of the total 121 cases, 106 were subject to analysis of clinical efficacy, including 38 cases in the HR 0.5 g group, 32 in the HR 1.0 g group, and 36 in the CAZ group. Efficacy rates in the assessment by the committee were 84.2% for the HR 0.5 g group, 75.0% for the HR 1.0 g group, and 86.1% for the CAZ group, without any significant difference between the 3 groups. The bacterial elimination rates were 73.9%, 75.0% m and 88.5%, respectively, without any significant difference between the 3 groups. Associated reactions were noted in 2 of 36 cases in the HR 1.0 g group (eruption and diarrhea), but not in the other 2 groups. The incidence of abnormal clinical laboratory findings was 23.1% in the HR 0.5 g group, 22.2% in the HR 1.0 g group, and 22.5% in the CAZ group, without any significant difference between the 3 groups. Utility rates were 84.2% for the HR 0.5 g group, 74.2% for the HR 1.0 g group, and 86.1% for the CAZ group, without any significant difference between the 3 groups. The HR 0.5 g and 1.0 groups showed no difference in clinical efficacy, bacteriological response, safety, and utility against RTI, and the results of both groups were about equal to those of the CAZ group.
Databáze: OpenAIRE
Externí odkaz: